An observational cohort study of extended dosing (once every 2 weeks or once monthly) regimens with darbepoetin alfa in patients with chronic kidney disease not on dialysis: The EXTEND study

Nephrology Dialysis Transplantation

Volumn 27, Issue 6, 2012, Pages 2303-2311

  Galle, Jan Christoph ^a   Claes, Kathleen ^b   Kiss, Istvan ^c   Winearls, Christopher G ^d   Herlitz, Hans ^e   Guerin, Alain ^f   Di Giulio, Salvatore ^g   Suranyi, Michael G ^h   Bridges, Ian ⁱ   Addison, Janet ⁱ   Farouk, Mourad ^j  

^a Klinikum Ludenscheid   (Germany)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c Szent Imre Hospital   (Hungary)

^d OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^e UNIVERSITY OF GOTHENBURG   (Sweden)

^f INSERM   (France)

^g SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^h LIVERPOOL HOSPITAL   (Australia)

ⁱ AMGEN LTD   (United Kingdom)

^j AMGEN INC   (United States)

more..

Author keywords

Anaemia; Chronic kidney disease; Darbepoetin alfa; Erythropoiesis stimulating agent

Indexed keywords

ANTIANEMIC AGENT; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

AGED; ANEMIA; ARTICLE; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; ERYTHROCYTE APLASIA; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; INFLUENZA; INJECTION SITE REACTION; LEUKOPENIA; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PANCREAS CARCINOMA; PHLEBITIS; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY; SUBDURAL HEMATOMA; TACHYCARDIA; VERTIGO;

ADULT; AGED; ANEMIA; ERYTHROPOIETIN; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HEMATINICS; HUMANS; KIDNEY FAILURE, CHRONIC; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84861873131     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr677     Document Type: Article

References (34)

1. Cody J, Daly C, Campbell M et al. Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients. Cochrane Database Syst Rev 2005(3): CD003266
2. Toto RD, Pichette V, Navarro J et al. Darbepoetin alfa effectively treats anemia in patients with chronic kidney disease with de novo every-other-week administration. Am J Nephrol 2004; 24: 453-460
3. Suranyi MG, Lindberg JS, Navarro J et al. Treatment of anemia with darbepoetin alfa administered de novo once every other week in chronic kidney disease. Am J Nephrol 2003; 23: 106-111
4. Agarwal AK, Silver MR, Reed JE et al. An open-label study of darbepoetin alfa administered once monthly for the maintenance of haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis. J Intern Med 2006; 260: 577-585
5. Disney A, Jersey PD, Kirkland G et al. Darbepoetin alfa administered monthly maintains haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis: a multicentre, openlabel, Australian study. Nephrology (Carlton) 2007; 12: 95-101
6. Burnier M, Douchamps JA, Tanghe A et al. Less frequent dosing of erythropoiesis stimulating agents in patients undergoing dialysis: a European multicentre cost study. J Med Econ 2009; 12: 77-86
7. Carrera F, Burnier M. Use of darbepoetin alfa in the treatment of anaemia of chronic kidney disease: clinical and pharmacoeconomic considerations. Nephrol Dial Transplant 2009; 2 (Suppl 1): i9-i17
8. Bernardo M, Crawford P, Hertel J et al. Assessment of time and practice resources required to provide weekly or monthly erythropoiesisstimulating protein therapy to chronic kidney disease patients in the physician office setting. J Manag Care Pharm 2006; 12: 714-725
9. Silver MR, Geronemus R, Krause M et al. Anaemia treatment with Q2W darbepoetin alfa in patients with chronic kidney disease naive to erythropoiesis-stimulating agents. Curr Med Res Opin 2009; 25: 123-131
10. Hertel J, Locay H, Scarlata D et al. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR). Am J Nephrol 2006; 26: 149-156
11. US Renal Data System. USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2009.
12. Locatelli F, Covic A, Macdougall IC et al. ORAMA: a study to investigate EBPG impact on renal anaemia-design and baseline data. J Nephrol 2008; 21: 592-603
13. De Nicola L, Conte G, Chiodini P et al. Stability of target hemoglobin levels during the first year of epoetin treatment in patients with chronic kidney disease. Clin J Am Soc Nephrol 2007; 2: 938-946
14. Drueke TB, Locatelli F, Clyne N et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071-2084
15. Singh AK, Szczech L, Tang KL et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098
16. Locatelli F, Covic A, Eckardt KU et al. Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrol Dial Transplant 2009; 24: 348-354
17. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 2007; 50: 471-530
18. Pfeffer MA, Burdmann EA, Chen CY et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019-2032
19. Locatelli F, Aljama P, Canaud B et al. Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to Reduce Cardiovascular Events with Aranesp(R) Therapy (TREAT) Study. Nephrol Dial Transplant 2010; 25: 2846-2850
20. Rossert J, Gassmann-Mayer C, Frei D et al. Prevalence and predictors of epoetin hyporesponsiveness in chronic kidney disease patients. Nephrol Dial Transplant 2007; 22: 794-800
21. DeFrancisco AL, Macdougall IC, Carrera F et al. Intercurrent events and comorbid conditions influence hemoglobin level variability in dialysis patients. Clin Nephrol 2009; 71: 397-404
22. Fishbane S, Berns JS. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int 2005; 68: 1337-1343
23. Boudville NC, Djurdjev O, Macdougall IC et al. Hemoglobin variability in nondialysis chronic kidney disease: examining the association with mortality. Clin J Am Soc Nephrol 2009; 4: 1176-1182
24. Minutolo R, Chiodini P, Cianciaruso B et al. Epoetin therapy and hemoglobin level variability in nondialysis patients with chronic kidney disease. Clin J Am Soc Nephrol 2009; 4: 552-559
25. Lawler EV, Bradbury BD, Fonda JR et al. Transfusion burden among patients with chronic kidney disease and anemia. Clin J Am Soc Nephrol 2010; 5: 667-672
26. Pillans P. Clinical perspectives in drug safety and adverse drug reactions. Expert Rev Clin Pharmacol 2008; 1: 695-705
27. Henke M, Laszig R, Rube C et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003; 362: 1255-1260
28. Keith DS, Nichols GA, Gullion CM et al. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004; 164: 659-663
29. London R, Solis A, Goldberg GA et al. Health care resource utilization and the impact of anemia management in patients with chronic kidney disease. Am J Kidney Dis 2002; 40: 539-548
30. Foley RN, Murray AM, Li S et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 2005; 16: 489-495
31. Levin A, Djurdjev O, BeaulieuMet al. Variability and risk factors for kidney disease progression and death following attainment of stage 4 CKD in a referred cohort. Am J Kidney Dis 2008; 52: 661-671
32. Voormolen N, Grootendorst DC, Urlings TA et al. Prevalence of anemia and its impact on mortality and hospitalization rate in predialysis patients. Nephron Clin Pract 2010; 115: c133-c141
33. Khan SS, Kazmi WH, Abichandani R et al. Health care utilization among patients with chronic kidney disease. Kidney Int 2002; 62: 229-236
34. Roger SD, Levin A. Epoetin trials: randomised controlled trials don't always mimic observational data. Nephrol Dial Transplant 2007; 22: 684-686